- Home
- DARE
DARE
Dare Bioscience Inc.
as 03-28-2025 4:00pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $20.33 | AVG Volume (30 days): | 18.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.67 - $7.56 | Next Earning Date: | 05-13-2025 |
| Revenue: | $1,881,316 | Revenue Growth: | 88.13% |
| Revenue Growth (this year): | -49.78% | Revenue Growth (next year): | 136.52% |
Latest Dare Bioscience Inc. News
DARE Breaking Stock News: Dive into DARE Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025
GlobeNewswire
a month ago
Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant
GlobeNewswire
2 months ago
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
GlobeNewswire
3 months ago
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
MT Newswires
3 months ago
Dare Bioscience to Submit Plan for Phase 3 Study of Potential Female Sexual Disorder Treatment
GlobeNewswire
3 months ago
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
GlobeNewswire
4 months ago
Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
GlobeNewswire
4 months ago
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Compare DARE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DARE Dare Bioscience Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.